Turan Eray Seven

Turan Eray Seven

Auto-generated profile, based on publicly available information

Turan Eray Seven

Department of Surgical Oncology, Ankara Sincan Training and Research Hospital, Sincan/Ankara, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Turkish Journal of Surgery
Verified
Journal Article
Open access
PDF file
RKRamazan KOZAN
Ramazan KOZAN
İTİlhan Taşdöven
İlhan Taşdöven
TSTuran Eray Seven
Turan Eray Seven
SASelim Aydemir
Selim Aydemir
BGBanu Doğan Gün
Banu Doğan Gün
MCMustafa Cömert
Mustafa Cömert
Gardner’s syndrome (GS) is a very rare autosomal dominant multisystem disease. Osteomas, skin and soft tissue tumors are present with gastrointestinal polyposis. The polyps have very high malignancy potentials. If prophylactic resection is not performed, colorectal cancer development is inevitable in all patients with GS. Polyposis is usually asymptomatic. Therefore, careful evaluation of extraintestinal findings of the disease is very important for early diagnosis. In this article, diagnosis and treatment of GS are presented in monozygotic twins, which have not been previously described in the literature. The diagnostic process, which started with dental complaints of one case, was carried out in an effective manner and then, prophylactic surgery was performed in twins. This article aimed to make clinicians and dentists attentive for early diagnosis of disease and to review treatment options.

13 June 2025 in Journal of Surgical Research
Verified
Journal Article
Closed access
TSTuran Eray Seven
Turan Eray Seven
KKKemal Karakaya
Kemal Karakaya
BGBerrak Güven
Berrak Güven
YBYilmaz Baş
Yilmaz Baş
FKFürüzan Köktürk
Fürüzan Köktürk

24 February 2026 in Journal of Comprehensive Surgery
Verified
Journal Article
Closed access
TSTuran Eray Seven
Turan Eray Seven
HAHüseyin Hakan Amioğlu
Hüseyin Hakan Amioğlu
GKGökhan Karaca
Gökhan Karaca
Aims: Appendectomy is one of the most frequently performed surgical procedures for acute abdominal pain. Appendectomy specimens submitted for pathology often show inflammatory changes, but a small percentage of incidental neoplasms can also be detected. Methods: This study included all patients who underwent appendectomy at our institution between August 2022 and August 2025. All appendix specimens removed, regardless of the indication for surgery, were included. Pathology reports were retrieved from the electronic archive and combined to identify each patient individually. Results: A total of 1168 appendectomy cases were included in the study. The patient ages ranged from 7 to 84 years. The median age was 33 (IQR: 24–42) years, and the mean age was 34.6 ± 12.5 years. 690 patients (59.1%) were male, 477 patients (40.8%) were female; gender information was not available for 1 patient. A total of 3 malignant cases were identified. Malignancy subtypes were recorded according to morphology codes as carcinoid tumor/NET (8240/3) and unspecified malignant neoplasia (8000/3). Additionally, 4 cases were reported as low-grade appendiceal mucinous neoplasm (LAMN). The ages of the LAMN cases ranged from 35 to 65 years, with two patients being male and two being female. Conclusion: This study demonstrated that the incidence of malignancy in appendectomies is low, but different histological types, although rare, can be observed, which can alter clinical management. In addition to malignant subtypes such as neuroendocrine tumors and adenocarcinoma, LAMN cases should be carefully reported as a separate category. The fact that LAMNs can lead to complications such as pseudomyxoma peritonei increases the clinical importance of these lesions. The obtained data highlight the necessity of detailed histopathological examination of every appendectomy specimen. Furthermore, contributing current incidence data from our country to the literature may help both standardize pathological reporting and determine postoperative follow-up strategies.

3 November 2025
Verified
Book
Open access
PDF file
SŞSunay Şengezer
Sunay Şengezer
İAİsmail Aydın
İsmail Aydın
HCHatice Coşkun
Hatice Coşkun
GGGökmen Güzel
Gökmen Güzel
MÇMuhammet Ömer Çetinkaya
Muhammet Ömer Çetinkaya
TSTuran Eray Seven
Turan Eray Seven

29 November 2025 in Journal of Comprehensive Surgery
Verified
Journal Article
Open access
PDF file
TSTuran Eray Seven
Turan Eray Seven
Peritoneal metastases (PM) are a common clinical entity in gastrointestinal and gynecological malignancies, often characterized by advanced stages and a poor prognosis. The presence of PM, particularly in colorectal and gastric cancers, has historically been associated with short survival and limited treatment options. The inherent peritoneal-plasma barrier and limited drug diffusion to tumor nodules have historically limited the effectiveness of systemic chemotherapy at peritoneal surfaces. This process has been radically altered since the 1980s by the locoregional treatment approach pioneered by Paul H. Sugarbaker. Sugarbaker conceptualized peritoneal surface malignancies as a potentially "local-regional" disease site, exhibiting a different biology than systemic metastases; He defined a treatment paradigm consisting of the removal of macroscopic tumor burden with cytoreductive surgery (CRS) and targeting residual microscopic disease with hyperthermic intraperitoneal chemotherapy (HIPEC). Most reviews in the existing literature address CRS+HIPEC treatment solely from a surgical and chemotherapeutic perspective. This study offers a multidisciplinary perspective by examining the historical framework from Sugarbaker to the present, biomarker-based selection, artificial intelligence-supported patient assessment models, and data standardization initiatives. The idea that peritoneal surface malignancies have a disease biology distinct from systemic metastasis emerged in the 1980s with a conceptual revolution pioneered by Paul H. Sugarbaker. Sugarbaker redefined the peritoneal cavity as a "treatable anatomical compartment." Thus, a locoregional approach has been developed that aims to overcome the limitations of systemic therapy. The combination of CRS (cytoreductive surgery) and HIPEC is an approach that aims to achieve loco-regional control in peritoneal metastases. However, its effectiveness is sensitive to the primary tumor type, tumor burden (PCI), degree of surgical completeness (CC score), the HIPEC protocol used, and center experience. This section summarizes current evidence for peritoneal metastases from colorectal, ovarian, and gastric cancer (CRC-PM, EOC-PM, GC-PM). Current evidence suggests that cytoreductive surgery (CRS) is the strongest prognostic factor in the management of peritoneal metastases, while HIPEC may provide an additional survival advantage in carefully selected cases with appropriate agent, temperature, and duration parameters. However, current data are still limited due to protocol heterogeneity, agent differences, and variability in patient selection criteria. In the future, thanks to the integration of molecular biomarker-based selection strategies, AI-assisted imaging analyses, and international data-sharing networks (e.g., PSOGI, RENAPE), the CRS+HIPEC approach will become much more individualized, predictable, and standardized. This multifaceted advancement holds the potential to optimize not only survival but also treatment safety and quality of life in the treatment of peritoneal metastases.

3 November 2025
Verified
Book Chapter
Open access
PDF file
TSTuran Eray Seven
Turan Eray Seven
Malign melanom, melanosit kökenli, çoğunlukla deri yerleşimli olmakla birlikte mukozalarda ve nadiren oküler bölgede görülebilen agresif